Novo Nordisk Slides on Pressure From Lilly’s Pill Study

WATCH: Lilly’s study is putting pressure on Novo, as Bloomberg Intelligence’s Sam Fazeli explains.Source: Bloomberg

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Marthe Fourcade

April 22, 2025 at 3:07 AM EDT

Updated on

April 22, 2025 at 4:42 AM EDT

Novo Nordisk A/S slumped amid concern that a weight-loss pill from rival Eli Lilly & Co. will steal market share from bestsellers such as its injected blockbuster Ozempic.

The stock dropped as much as 9.8% to 380 kroner on the first trading day since Lilly said that an experimental pill helped patients shed weight and control blood sugar about as well as Ozempic.